The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A randomized phase II study of pazopanib in castrate-sensitive prostate cancer: A University of Chicago phase II consortium/DoD Prostate Cancer Clinical Trials Consortium study.
James Edward Ward
No relevant relationships to disclose
Suwicha Limvorasak
No relevant relationships to disclose
Ted Karrison
No relevant relationships to disclose
Gurkamal S. Chatta
No relevant relationships to disclose
Maha Hussain
No relevant relationships to disclose
Daniel H. Shevrin
No relevant relationships to disclose
Russell Zelig Szmulewitz
No relevant relationships to disclose
Walter M. Stadler
No relevant relationships to disclose
Edwin M. Posadas
No relevant relationships to disclose